STAC-9

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.[1][2][3]

STAC-9
Identifiers
  • N-pyridin-4-yl-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine-1-carboxamide
PubChem CID
UNII
Chemical and physical data
FormulaC20H15F3N4O
Molar mass384.362 g·mol−1
3D model (JSmol)
  • C1CN(C2=C1C=CC(=N2)C3=CC(=CC=C3)C(F)(F)F)C(=O)NC4=CC=NC=C4
  • InChI=1S/C20H15F3N4O/c21-20(22,23)15-3-1-2-14(12-15)17-5-4-13-8-11-27(18(13)26-17)19(28)25-16-6-9-24-10-7-16/h1-7,9-10,12H,8,11H2,(H,24,25,28)
  • Key:WFPOEJCACZIDSN-UHFFFAOYSA-N

See also

References
  1. US 9556201, Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS, "Bicyclic pyridines and analogs as sirtuin modulators.", published 4 October 2012, assigned to Sitris Pharmaceuticals and GlaxoSmithKline
  2. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. (March 2013). "Evidence for a common mechanism of SIRT1 regulation by allosteric activators". Science. 339 (6124): 1216–9. Bibcode:2013Sci...339.1216H. doi:10.1126/science.1231097. PMC 3799917. PMID 23471411.
  3. Thevis M, Schänzer W (March 2016). "Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs". Rapid Communications in Mass Spectrometry. 30 (5): 635–51. Bibcode:2016RCMS...30..635T. doi:10.1002/rcm.7470. PMID 26842585.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.